Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurology and Therapy
Published in: Neurology and Therapy 2/2020

Open Access 01-12-2020 | Multiple Sclerosis | Review

Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region

Authors: Raed Alroughani, Jihad Inshasi, Abdullah Al-Asmi, Jaber Alkhabouri, Taoufik Alsaadi, Abdullah Alsalti, Amir Boshra, Beatriz Canibano, Samar Farouk Ahmed, Ahmed Shatila

Published in: Neurology and Therapy | Issue 2/2020

Login to get access

Abstract

Most disease-modifying drugs (DMDs) are contraindicated in pregnancy. Management of MS is especially challenging for pregnant patients, as withdrawal of DMDs leave the patient at risk of increased disease activity. We, a group of experts in MS care from countries in the Arab Gulf, present our consensus recommendations on the management of MS in these patients. Where possible, a patient planning pregnancy can be switched to a DMD considered safe in this setting. Interferon β now can be used during pregnancy, where there is a clinical need to maintain treatment, in addition to glatiramer acetate. Natalizumab (usually to 30 weeks’ gestation for patients with high disease activity at high risk of relapse and disability progression) may also be continued into pregnancy. Cladribine tablets and alemtuzumab have been hypothesised to act as immune reconstitution therapies (IRTs). These drugs provide a period of prolonged freedom from relapses for many patients, but the patient must be prepared to wait for up to 20 months from initiation of therapy before becoming pregnant. If a patient becomes pregnant while taking fingolimod, and requires continued DMD treatment, a switch to interferon β or natalizumab after a variable washout period may be prescribed, depending on the level of disease activity. Women who wish to breastfeed should be encouraged to do so, and interferon β may also be used during breastfeeding. There is a lack of data regarding the safety of using other DMDs during breastfeeding.
Literature
1.
2.
GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:269–85.CrossRef
3.
Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9:520–32.PubMedCrossRef
4.
Bove R, Chitnis T. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler. 2014;20:520–6.PubMedCrossRef
5.
Al Tahan AM, Alsharoqi I, Bohlega SA, et al. Characteristics of multiple sclerosis in the Middle East with special reference to the applicability of international guidelines to the region. Int J Neurosci. 2014;124:635–41.PubMedCrossRef
6.
Heydarpour P, Khoshkish S, Abtahi S, Moradi-Lakeh M, Sahraian MA. Multiple sclerosis epidemiology in Middle East and North Africa: a systematic review and meta-analysis. Neuroepidemiology. 2015;44:232–44.PubMedCrossRef
7.
Nasr Z, Etemadifar M, Khalili N. Epidemiology of multiple sclerosis in the Middle East: a systematic review and meta analysis. Mult Scler Relat Disord. 2014;3:744.CrossRef
8.
9.
10.
Mendibe Bilbao M, Boyero Durán S, Bárcena Llona J, Rodriguez-Antigüedad A. Multiple sclerosis: pregnancy and women's health issues. Neurologia. 2019;34:259–69.PubMedCrossRef
11.
Smeltzer SC. Reproductive decision making in women with multiple sclerosis. J Neurosci Nurs. 2002;34:145–57.PubMedCrossRef
12.
Carvalho AT, Veiga A, Morgado J, et al. Multiple sclerosis and motherhood choice: an observational study in Portuguese women patients. Rev Neurol. 2014;59:537–42.PubMed
13.
Riñon A, Buch M, Holley D, Verdun E. The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis. Patient Prefer Adherence. 2011;5:629–43.PubMedPubMedCentral
14.
Wicks P, Brandes D, Park J, Liakhovitski D, Koudinova T, Sasane R. Preferred features of oral treatments and predictors of non-adherence: two web-based choice experiments in multiple sclerosis patients. Interact J Med Res. 2015;4(1):e6.PubMedPubMedCentralCrossRef
15.
Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. Pract Neurol. 2019;19:106–14.PubMedCrossRef
16.
17.
Alroughani R, Inshasi JS, Deleu D, et al. An overview of high-efficacy drugs for multiple sclerosis: Gulf region expert opinion. Neurol Ther. 2019;8:13–23.PubMedPubMedCentralCrossRef
18.
AlJumah M, Marwan Alkhawajah M, Qureshi S, et al. Cladribine tablets and relapsing–remitting multiple sclerosis: a pragmatic, narrative review of what physicians need to know. Neurol Ther. 2020;9:11–23.PubMedPubMedCentralCrossRef
19.
20.
21.
22.
Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. 1998;339:285–91.PubMedCrossRef
23.
Hellwig K, Gold R. Family planning and multiple sclerosis. Akt Neurol. 2010;37:292–303.CrossRef
24.
Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96–120.PubMedCrossRef
25.
26.
Amato MP, Bertolotto A, Brunelli R, et al. Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach (published correction appears in Neurol Sci. 2017 Dec 26). Neurol Sci. 2017;38:1849–58.PubMedCrossRef
27.
Alroughani R, Akhtar S, Zeineddine M, et al. Risk of relapses during pregnancy among multiple sclerosis patients. Mult Scler Relat Disord. 2019;34:9–13.PubMedCrossRef
28.
Trojano M, Bergamaschi R, Amato MP, et al. The Italian multiple sclerosis register. Neurol Sci. 2019;40:155–65.PubMedCrossRef
29.
Giannini M, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after Glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 2012;12:124.PubMedPubMedCentralCrossRef
30.
Herbstritt S, Langer-Gould A, et al. Glatiramer acetate during early pregnancy: a prospective cohort study. Mult Scler. 2016;22:810–6.PubMedCrossRef
31.
Sandberg-Wollheim M, Neudorfer O, Grinspan A, et al. Pregnancy outcomes from the branded glatiramer acetate pregnancy database. Int J MS Care. 2018;20:9–14.PubMedPubMedCentralCrossRef
32.
Gold R, Phillips JT, Havrdova E, et al. Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol Ther. 2015;4:93–104.PubMedPubMedCentralCrossRef
33.
34.
Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology. 2010;75:1794–802.PubMedCrossRef
35.
Thiel S, Langer-Gould A, Rockhoff M, et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—a prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler. 2016;22:801–9.PubMedCrossRef
36.
Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler. 2011;17:423–30.PubMedCrossRef
37.
38.
Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing–remitting multiple sclerosis. Neurol Ther. 2014;3:133–8.PubMedPubMedCentralCrossRef
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2015;21:198–205.PubMedCrossRef
49.
Portaccio E, Annovazzi P, Ghezzi A, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology. 2018;90:e823–e831831.PubMed
50.
Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 2016;16:150.PubMedPubMedCentralCrossRef
51.
Triplett JD, Vijayan S, Rajanayagam S, Tuch P, Kermode AG. Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use. Mult Scler Relat Disord. 2020;40:101961.PubMedCrossRef
52.
53.
Lünemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H. Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol. 2020;16:56–62.PubMedCrossRef
54.
55.
Bearak J, Popinchalk A, Alkema L, Sedgh G. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. Lancet Glob Health. 2018;6:e380–e389389.PubMedPubMedCentralCrossRef
56.
Haghikia A, Langer-Gould A, Rellensmann G, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71:891–5.PubMedCrossRef
57.
Miller AE. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis. Clin Ther. 2015;37:2366–80.PubMedCrossRef
58.
59.
Barry B, Erwin AA, Stevens J, Tornatore C. Fingolimod rebound: a review of the clinical experience and management considerations. Neurol Ther. 2019;8:241–50.PubMedPubMedCentralCrossRef
60.
Portaccio E, Moiola L, Martinelli V, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: maternal risks. Neurology. 2018;90:e832–e839839.PubMed
61.
Sepúlveda M, Montejo C, Llufriu S, et al. Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: analysis of predisposing factors. Mult Scler Relat Disord. 2019;38:101483.PubMedCrossRef
62.
Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1756286419837809.PubMedPubMedCentralCrossRef
63.
64.
Alroughani R, Alowayesh MS, Ahmed SF, Behbehani R, Al-Hashel J. Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. Neurology. 2018;90:e840–e846846.PubMedCrossRef
65.
Ladeira F, Braz L, Salgado P, Vaz S. A multicenter, non-interventional study to evaluate the disease activity in multiple sclerosis after withdrawal of Natalizumab in Portugal. Clin Neurol Neurosurg. 2019;184:105390.PubMedCrossRef
66.
Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62:385–92.PubMedCrossRef
67.
68.
69.
Rolfes L, Pfeuffer S, Ruck T, et al. Therapeutic apheresis in acute relapsing multiple sclerosis: current evidence and unmet needs-a systematic review. J Clin Med. 2019;8:E1623.CrossRef
Metadata
Title
Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region
Authors
Raed Alroughani
Jihad Inshasi
Abdullah Al-Asmi
Jaber Alkhabouri
Taoufik Alsaadi
Abdullah Alsalti
Amir Boshra
Beatriz Canibano
Samar Farouk Ahmed
Ahmed Shatila
Publication date
01-12-2020
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue 2/2020
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-020-00201-8

Other articles of this Issue 2/2020

Neurology and Therapy 2/2020 Go to the issue

Original Research

Impact of Formulary Restrictions on Antiepileptic Drug Dispensation Outcomes

Commentary

Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing–Remitting Multiple Sclerosis Patients

Original Research

Management of Migraine and the Accessibility of Specialist Care: Findings from an Extended Multinational Survey (My Migraine Center Survey)

Review

Could Early Identification of Changes in Olfactory Function Be an Indicator of Preclinical Neurodegenerative Disease? A Systematic Review

Review

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis

Review

CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer’s Disease—A Narrative Review